CR20230452A - Composiciones que contienen análogos de incretina y usos de estas - Google Patents
Composiciones que contienen análogos de incretina y usos de estasInfo
- Publication number
- CR20230452A CR20230452A CR20230452A CR20230452A CR20230452A CR 20230452 A CR20230452 A CR 20230452A CR 20230452 A CR20230452 A CR 20230452A CR 20230452 A CR20230452 A CR 20230452A CR 20230452 A CR20230452 A CR 20230452A
- Authority
- CR
- Costa Rica
- Prior art keywords
- containing compositions
- incretin analog
- incretin
- dyslipidemia
- obesity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporciona una composición que incluye un análogo de incretina con actividad en cada uno de los receptores de polipéptido insulinotrópico dependiente de glucosa (GIP), de péptido similar al glucagón tipo 1 (GLP-1) y de glucagón (GCG) (es decir, agonista triple de receptores) y uno o más agentes adicionales como un agente de tonicidad y un conservante. También se proporcionan métodos para tratar enfermedades como la diabetes mellitus tipo 2, la dislipidemia, el síndrome metabólico, la enfermedad de hígado graso no alcohólica, la esteatohepatitis no alcohólica y la obesidad con la composición.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164702P | 2021-03-23 | 2021-03-23 | |
| PCT/US2022/021309 WO2022204117A1 (en) | 2021-03-23 | 2022-03-22 | Incretin analog-containing compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230452A true CR20230452A (es) | 2023-10-11 |
Family
ID=81580297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230452A CR20230452A (es) | 2021-03-23 | 2022-03-22 | Composiciones que contienen análogos de incretina y usos de estas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20240173250A1 (es) |
| EP (1) | EP4312982A1 (es) |
| JP (1) | JP2024513754A (es) |
| KR (1) | KR20230146645A (es) |
| CN (1) | CN117042754A (es) |
| AR (1) | AR125086A1 (es) |
| AU (2) | AU2022246002B2 (es) |
| BR (1) | BR112023016083A2 (es) |
| CA (1) | CA3213230A1 (es) |
| CL (1) | CL2023002808A1 (es) |
| CO (1) | CO2023012373A2 (es) |
| CR (1) | CR20230452A (es) |
| DO (1) | DOP2023000200A (es) |
| EC (1) | ECSP23071867A (es) |
| IL (1) | IL305688A (es) |
| JO (1) | JOP20230224A1 (es) |
| MX (1) | MX2023011278A (es) |
| PE (1) | PE20240238A1 (es) |
| TW (2) | TWI837615B (es) |
| UA (1) | UA129418C2 (es) |
| WO (1) | WO2022204117A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102812908B1 (ko) * | 2019-08-19 | 2025-05-28 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| CN119978101B (zh) * | 2024-07-30 | 2025-10-10 | 四川普康药业有限公司 | 多肽化合物及其应用 |
| WO2026059846A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | Dissolving microneedle patch for transdermal delivery of a peptide |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080200383A1 (en) * | 2005-04-08 | 2008-08-21 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent |
| UA101304C2 (ru) * | 2006-09-13 | 2013-03-25 | Смитклайн Бичам Корпорейшн | Способы введения гипогликемических средств продленного действия |
| TWI430806B (zh) * | 2006-09-13 | 2014-03-21 | Smithkline Beecham Corp | 用於投與長效降血糖藥劑之方法 |
| ES2548275T3 (es) | 2010-03-01 | 2015-10-15 | Eli Lilly And Company | Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble |
| CA2808978A1 (en) * | 2010-08-23 | 2012-03-01 | Shmuel Ben-Sasson | Compositions for gastric delivery of active agents |
| BR112014014898A2 (pt) * | 2011-12-22 | 2020-10-27 | Pfizer Inc. | processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2 |
| JP2015533483A (ja) * | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
| WO2018096460A1 (en) * | 2016-11-22 | 2018-05-31 | Biocon Research Limited | Pharmaceutical compositions of glp-1 analogues |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| WO2018213151A1 (en) * | 2017-05-18 | 2018-11-22 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation comprising incretin-insulin conjugates |
| TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
-
2022
- 2022-03-15 TW TW111109488A patent/TWI837615B/zh active
- 2022-03-15 TW TW113107533A patent/TW202423476A/zh unknown
- 2022-03-15 AR ARP220100594A patent/AR125086A1/es unknown
- 2022-03-22 AU AU2022246002A patent/AU2022246002B2/en active Active
- 2022-03-22 PE PE2023002682A patent/PE20240238A1/es unknown
- 2022-03-22 KR KR1020237032194A patent/KR20230146645A/ko active Pending
- 2022-03-22 IL IL305688A patent/IL305688A/en unknown
- 2022-03-22 JP JP2023558406A patent/JP2024513754A/ja active Pending
- 2022-03-22 EP EP22721153.9A patent/EP4312982A1/en active Pending
- 2022-03-22 CN CN202280023411.5A patent/CN117042754A/zh active Pending
- 2022-03-22 BR BR112023016083A patent/BR112023016083A2/pt unknown
- 2022-03-22 UA UAA202303908A patent/UA129418C2/uk unknown
- 2022-03-22 US US18/552,013 patent/US20240173250A1/en active Pending
- 2022-03-22 MX MX2023011278A patent/MX2023011278A/es unknown
- 2022-03-22 WO PCT/US2022/021309 patent/WO2022204117A1/en not_active Ceased
- 2022-03-22 CA CA3213230A patent/CA3213230A1/en active Pending
- 2022-03-22 CR CR20230452A patent/CR20230452A/es unknown
-
2023
- 2023-09-19 JO JOJO/P/2023/0224A patent/JOP20230224A1/ar unknown
- 2023-09-19 CO CONC2023/0012373A patent/CO2023012373A2/es unknown
- 2023-09-20 DO DO2023000200A patent/DOP2023000200A/es unknown
- 2023-09-21 CL CL2023002808A patent/CL2023002808A1/es unknown
- 2023-09-22 EC ECSENADI202371867A patent/ECSP23071867A/es unknown
-
2025
- 2025-09-25 AU AU2025238025A patent/AU2025238025A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3213230A1 (en) | 2022-09-29 |
| TW202423476A (zh) | 2024-06-16 |
| AU2025238025A1 (en) | 2025-10-23 |
| ECSP23071867A (es) | 2023-11-30 |
| US20240173250A1 (en) | 2024-05-30 |
| AU2022246002A1 (en) | 2023-08-24 |
| JOP20230224A1 (ar) | 2023-09-19 |
| IL305688A (en) | 2023-11-01 |
| CO2023012373A2 (es) | 2023-09-29 |
| EP4312982A1 (en) | 2024-02-07 |
| TWI837615B (zh) | 2024-04-01 |
| AR125086A1 (es) | 2023-06-07 |
| DOP2023000200A (es) | 2023-10-15 |
| PE20240238A1 (es) | 2024-02-16 |
| MX2023011278A (es) | 2023-10-04 |
| BR112023016083A2 (pt) | 2023-10-03 |
| AU2022246002B2 (en) | 2025-06-26 |
| JP2024513754A (ja) | 2024-03-27 |
| UA129418C2 (uk) | 2025-04-16 |
| KR20230146645A (ko) | 2023-10-19 |
| CL2023002808A1 (es) | 2024-06-21 |
| WO2022204117A1 (en) | 2022-09-29 |
| TW202302139A (zh) | 2023-01-16 |
| CN117042754A (zh) | 2023-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430550B1 (ar) | Glp-1r عوامل مساعدة لـ واستخداماتها | |
| PH12021551165A1 (en) | Glp-1r agonists and uses thereof | |
| CR20230452A (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| PH12019500097A1 (en) | Combination comprising a fungicidal strain and an active compound | |
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
| EP4691555A3 (en) | Incretin analogs and uses thereof | |
| ZA201807992B (en) | Method of treating liver fibrosis | |
| MY145628A (en) | Synergistic fungicidal compositions | |
| EA201390497A1 (ru) | Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия | |
| AU2003289854A1 (en) | Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents | |
| BRPI0409100A (pt) | composição conservante de madeira, e, métodos para conservar um produto de madeira e madeira | |
| GB0209749D0 (en) | Compositions and methods | |
| EP4596044A3 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
| MX2023005550A (es) | Inhibidores de diclorofenol hsd17b13 y usos de los mismos. | |
| WO2024165571A3 (en) | Inhibitors of expression and/or function | |
| MX2025000641A (es) | Composiciones y métodos para el tratamiento del trastorno metabólico y el hígado | |
| FR2931661B1 (fr) | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide. | |
| WO2004087076A3 (en) | Methods for inhibiting adipogenesis and for treating type 2 diabetes | |
| WO2021067611A3 (en) | Compositions and methods for treating alzheimer's disease | |
| UA92444C2 (uk) | Фунгіцидна суміш тритиконазолу і дифеноконазолу, композиція на її основі та спосіб боротьби зі шкідливими фітопатогенними грибами | |
| MX2009002228A (es) | Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo. | |
| BRPI0606191A2 (pt) | compostos de amino e carboxamido tetracìclicos e métodos do seu uso | |
| MX2023005142A (es) | Procedimiento enzimatico. | |
| BRPI0406734A (pt) | Composição termiticida, e, método para controlar térmitas | |
| FR2931662B1 (fr) | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise. |